B
Bull
Bull · 25%VIGL
$7.87
Precio del escenario
$8.050
0.000 (0.00%)Al cierre
Loading chart…
- High
- 8.095
- Open
- 8.050
- VWAP
- 8.06
- Vol
- 5.51M
- Mkt Cap
- 168.38M
- Low
- 8.040
- Amount
- 44.39M
- EV/EBITDA, TTM
- 0.02
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company, which is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, iluzanebart, is a fully human monoclonal antibody agonist targeting the triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The Company is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD).
Métricas de valoración
The current forward P/E ratio for Vigil Neuroscience Inc (VIGL) is -1.15, compared to its 5-year average forward P/E of -2.92.
Alphio AI Price Scenarios for VIGL
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.007-25BenzingaEli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
7.007-14PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, CHTR, VIGL on Behalf of Shareholders
7.007-03GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR, TASK, VIGL, STRM on Behalf of Shareholders
7.006-13GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRKN, ELEV, STR, VIGL on Behalf of Shareholders
7.006-13GlobenewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
VIGL FAQ — answered by Alphio AI
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company, which is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, iluzanebart, is a fully human monoclonal antibody agonist targeting the triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The Company is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.